Buffers – Navigating New Demands On Downstream Raw Materials

Publications
Published on:
May 27, 2021

The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing industry is the availability of materials that make up essential buffer components.
Buffers maintain defined conditions that help stabilize proteins through production, purification, formulation, and storage so their composition is important.

In March of 2021, Angela Linderholm, Jennifer Bratt, and Steven Chamow of Chamow & Associates, an Alira Health company, with S. Anne Montgomery co-authored a Q&A style article on topics related to buffer supply.

The article was included as part of an eBook, produced by BioProcess International, addressing the various concerns surrounding the issues of access to raw materials and the impact shortages will have downstream. In the article, several questions about maintaining sustainable relationships between consumers and suppliers, alternative energy sources, and contingency planning were posed to industry experts Laura Kaepplinger and Adi Kleinman. Their responses provide insight into the approaches that the industry is taking to mitigate risk and minimize production impact.

Read the full article, the BioProcess International eBook, “Buffers, navigating new demands on downstream raw materials” by Robert Shaw, Angela Linderholm, Jennifer Bratt, and Steven Chamow.

Related news

News June 17, 2022
Music Beats Cancer Hosts Reception at BIO International Convention in San Diego
Music Beats Cancer hosted a reception fostering a networking community for innovators working on promising solutions for cancer.
Crowdfunding Patient Centricity Research & Development
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
News April 5, 2022
Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia
We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)
Clinical MedTech Patient Engagement Pharma Regulatory Research & Development
Publications December 10, 2021
Leveraging Data Intelligence for Effective Opportunity Screening and Prioritization in Drug Discovery
Our biotech client needed an innovative, effective way to identify which binding sites and therapeutic indications they should target for the development of new therapeutic agents for(...)
Advanced Analytics Digital Health Pharma Research & Development
Events November 24, 2021
Event: Innovations In Wound Healing Annual Conference
Join Dr. Mitch Sanders for an exclusive poster session at this event.
Research & Development
Events October 20, 2021
Event: SAWC Fall 2021
Join Dr. Sanders at SAWC Fall in Las Vegas, NV.
Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Due Diligence Research & Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.